Abstract:Therapeutic Advances in Chronic Disease, Volume 15, Issue , January-December 2024. Background:Fecal microbiota transplantation (FMT) is a promising treatment for active ulcerative colitis (UC). Understanding patient preferences can identify treatment features that may impact treatment decisions, improve shared decision-making, and contribute to patient-centered care, which is especially important in the context of novel treatments like FMT.Objectives:We aimed to quantify preferences for active UC treatments, specifically FMT and biologics, and identify patient characteristics associated with different preference patterns.Design:This is a cross-sectional survey study.Methods:We administered a discrete choice experiment (DCE) survey to elicit preferences in a sample of Canadian adults with UC. DCE data were analyzed using a main-effects mixed logit model and used to predict uptake of hypothetical scenarios reflecting alternative combinations of treatment features. Latent class modeling identified heterogeneity in patient preference patterns.Results:Participants' (n = 201) mean age was 47.1 years (SD: 14.5 years), 58% were female, and most (84%) had at least some post-secondary education. Almost half were willing to undergo FMT. When considering treatments for active UC, the most important attributes were chance of remission and severity of rare unknown side effects. All else equal, participants were most likely to uptake treatment that involves oral capsules/pills. Participants in the class with the highest utility for chance of remission were younger, had more severe disease, and 58% indicated that they would be willing to undergo FMT.Conclusion:We identified characteristics of UC patients who are more likely to be interested in FMT using preference elicitation methods. Patient-centered care can be enhanced by knowing which patients are more likely to be interested in FMT, potentially improving satisfaction with and adherence to treatments for active UC to maximize the effectiveness of treatment while considering heterogeneity in patient preferences.Plain language summaryPatient preferences for active ulcerative colitis treatments and fecal microbiota transplantationBackground and aims:Fecal microbiota transplantation (FMT) is a promising new treatment for active ulcerative colitis. Questions remain around the benefits and risks of FMT treatment for patients with ulcerative colitis. Understanding how patients weigh the treatment features and how treatment features influence their decisions may improve shared decision-making and contribute to patient-centered care, which is especially important for novel treatments like FMT.Using an experimentally designed survey, we aimed to:1. Elicit patient preferences for features of active ulcerative colitis treatments, specifically FMT and biologics; and,2. Identify patient characteristics associated with different preference patterns.Results:We found that younger patients with more severe disease are more likely to try FMT for the treatment of active ulcerative colitis. Oral capsules/pills are the preferred mode of treatment administration.Conclusions:These findings can enhance patient-centered care by characterizing patients who are more likely to be interested in FMT. Aligning treatment with the features that are important to patients can potentially improve satisfaction with and adherence to treatments for active ulcerative colitis to maximize their effectiveness for individual patients.

P1077 Patients’ and Gastroenterologists’ Preferences on Outcomes and Medication Attributes for Ulcerative colitis

Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment

REAL-WORLD EXPERIENCE AND PERSPECTIVES ON THE TREATMENT OF ULCERATIVE COLITIS: RESULTS FROM A HEALTHCARE PROVIDER SURVEY

P467 Perception Gap Between Patients with Inflammatory Bowel Disease (IBD) and Physicians in China: A Cross-sectional Study

P1083 Patient preferences for Inflammatory Bowel Disease treatments: an international survey using a discrete choice experiment in partnership with EFCCA

Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study

Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation

P732 Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results

Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey

P520 Preferences towards treatment attributes among patients with Crohn’s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experiment

P377 Proportion of IBD patients with suboptimal control in daily clinical practice – real-world evidence from the IBD Podcast study

EXPLORING THE RELATIONSHIP BETWEEN PATIENT SYMPTOMS AND PROVIDER GOALS FOR MUCOSAL HEALING IN IBD: INSIGHTS FROM THE IBD QORUS SURVEY DATA

The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis

Do Patients’ and Physicians’ Perspectives Differ on Preferences for Irritable Bowel Syndrome Treatment?

PATIENT DECISION MAKING ABOUT UTILIZATION OF TREATMENT AND MANAGEMENT METHODS: TOWARD ENHANCED PROMOTION OF PREVENTIVE SELF-MANAGEMENT FOR ULCERATIVE COLITIS

Evaluation of the Symptoms and Clinical Characteristics of Crohn's Disease and Ulcerative Colitis That Affect Healthcare Providers' Treatment Choices

Healthcare Needs and Perceptions of People Living With Inflammatory Bowel Disease in Australia: A Mixed-Methods Study

P551 Benefit–risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study

Inflammatory bowel disease patients' expectations of care: Insights from a qualitative study

A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease

P254 Outcomes of endoscopic and histologic remission in ulcerative colitis under advanced therapy